Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma
This study is testing a new immunotherapy drug called Teclistamab and comparing it to standard medications for people with high-risk smoldering multiple myeloma. Since there are currently no approved treatments for this early, slow-growing stage of bone marrow cancer, this research aims to find ways to stop it from turning into active cancer.
You may be able to join if you are 18 or older and have been diagnosed with high-risk smoldering multiple myeloma based on specific blood and bone marrow tests. Certain health conditions, recent cancer treatments, or plans to have children may prevent you from participating.
Participants will be randomly assigned to receive either the new immunotherapy drug Teclistamab or a combination of standard medications called Lenalidomide and Dexamethasone. Your health and the response of your cancer cells will be closely monitored throughout the study.
This study is currently recruiting participants at locations in Denver, Colorado, Boston, Massachusetts, and Portland, Oregon. Your care team will guide you through the exact schedule and clinic visits.
- 1Testing Teclistamab against standard medications for high-risk smoldering multiple myeloma.
- 2Aims to find effective treatments before the early-stage cancer becomes active.
- 3Currently recruiting patients at select medical centers in the United States.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.